50,000 Shares in Vera Therapeutics, Inc. $VERA Purchased by Swedbank AB

Swedbank AB bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $1,453,000. Swedbank AB owned about 0.08% of Vera Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. Vestal Point Capital LP grew its position in shares of Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in Vera Therapeutics by 7.7% during the second quarter. Geode Capital Management LLC now owns 1,294,958 shares of the company’s stock worth $30,513,000 after purchasing an additional 92,149 shares during the last quarter. American Century Companies Inc. lifted its stake in Vera Therapeutics by 89.3% during the second quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock worth $16,832,000 after purchasing an additional 336,978 shares during the last quarter. MPM Bioimpact LLC boosted its holdings in Vera Therapeutics by 35.4% in the second quarter. MPM Bioimpact LLC now owns 563,075 shares of the company’s stock worth $13,266,000 after purchasing an additional 147,356 shares during the period. Finally, Bank of America Corp DE increased its stake in Vera Therapeutics by 73.7% during the second quarter. Bank of America Corp DE now owns 394,280 shares of the company’s stock valued at $9,289,000 after purchasing an additional 167,264 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 3.8%

Shares of VERA stock opened at $53.58 on Friday. The business’s fifty day moving average is $36.26 and its 200-day moving average is $28.27. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $56.05. The stock has a market cap of $3.43 billion, a PE ratio of -13.43 and a beta of 1.21. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the previous year, the company posted ($0.85) EPS. Equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on VERA shares. Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a report on Friday, December 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Friday, November 28th. Finally, The Goldman Sachs Group boosted their price objective on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $74.83.

Insider Buying and Selling

In other Vera Therapeutics news, Director Patrick G. Enright bought 5,882 shares of Vera Therapeutics stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the acquisition, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the sale, the senior vice president owned 47,839 shares of the company’s stock, valued at $1,390,201.34. This trade represents a 23.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 16.30% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.